KRAS and non-small cell lung carcinoma: As expected, compound 0375-0604 reduced the levels of phosphorylation of CRAF and AKT in a dose-dependent manner in all three NSCLC cell lines (Figure 5), which indicated that compound 0375-0604 may block oncogenic KRAS function through inhibiting its downstream signaling pathways.